Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Compact Device Developed for Sorting Cells and Biomolecules

By LabMedica International staff writers
Posted on 20 Nov 2017
Biomolecules and cells circulating in the blood carry diagnostic information, the analysis of which makes highly effective, individualized therapies possible.

A microchip-based diagnostic device has been developed that analyzes and sorts clinically relevant biomolecules and cells in a blood test with light. More...
As a result, physicians can make early diagnoses, for example, of tumor and cardiovascular diseases and initiate patient-specific therapies with great efficacy.

Biomedical engineers at the Fraunhofer Institute of Laser Technology (Aachen, Germany) have developed the “AnaLighter” which is a compact diagnostic device for sorting cells and biomolecules. Its technological core is based on an optically switchable microfluidic chip whose optical sensors and switches are connected to the chip via optical fibers. The “Microchip Based Fluorescence Activated Cell Sorter” (μFACS) functions in the following way: The biomolecules and cells to be analyzed by fluorescence are guided through a microfluidic channel and focused hydrodynamically on a cross-section of 10 μm at the site of the optical measurement. Laser light from an optical fiber stimulates the analyte in the microfluidic channel to fluoresce.

Then, micro-optics focus the laser light emerging from the fiber into the microfluidic channel, collect the fluorescent light generated there and guide it through optical fibers to the photodetector. This fiber-optic design allows a significant reduction in the installation space and makes the μFACS more rugged compared to the prior state-of-the-art. The “AnaLighter technology” is, therefore, ideally suited for automated diagnostic applications in 24/7 operation.

The spectrally separated detection channels of the “AnaLighter” can simultaneously detect different marker molecules in the blood. In such multiplex diagnostics, these marker molecules from a blood sample are specifically bound by a mixture of microparticles, each particle species binding exactly one molecule species to be detected. The μFACS technology can also process water-in-oil emulsions in addition to aqueous solutions in contrast to conventional FACS systems.

The detection of bound marker molecules is encoded by a characteristic fluorescence label and its signal measured by one of the 16 detection channels. Such multiplex diagnosis can detect up to 16 different disease markers with only one measurement run. In annual routine checks, a general practitioner can detect a large number of possible diseases early in the course of a single blood test in order to prevent widespread diseases, such as cardiovascular disease. The sorting function also makes it possible to separate out the appropriate candidates from the others during screening, in order to dispose of the relevant gene sequences in for example genetically modified variants. The device was demonstrated at the COMPAMED 2017 held November 13-16, 2017, in Düsseldorf, Germany.

Related Links:
Fraunhofer Institute of Laser Technology


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.